Dogwood Therapeutics, Inc. Proceeds from Related Party Debt
Dogwood Therapeutics, Inc. (DWTX) reported Proceeds from Related Party Debt of $3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRelatedPartyDebt · last filed 2026-08-14
- Dogwood Therapeutics, Inc. proceeds from related party debt for the quarter ending 2025-12-31 was $0.00.
- Dogwood Therapeutics, Inc. proceeds from related party debt for the quarter ending 2025-09-30 was $0.00.
- Dogwood Therapeutics, Inc. proceeds from related party debt for the quarter ending 2025-06-30 was $0.00.
- Dogwood Therapeutics, Inc. proceeds from related party debt for the quarter ending 2025-03-31 was $3.00M.
- Dogwood Therapeutics, Inc. proceeds from related party debt for fiscal 2025 was $3.00M, a 80.42% decline from fiscal 2024.
- Dogwood Therapeutics, Inc. proceeds from related party debt for fiscal 2024 was $15.32M.
| Period end | Proceeds from Related Party Debt 3 month | Proceeds from Related Party Debt 6 month | Proceeds from Related Party Debt 9 month | Proceeds from Related Party Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $3.00M 10-K · filed 2026-03-18 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $3.00M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.00M 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $15.32M 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |